Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
about
The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinomaPathogen recognition and activation of the innate immune response in zebrafishNeutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patientsTIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceImmunobiology of hepatocarcinogenesis: Ways to go or almost there?The dual role of complement in cancer and its implication in anti-tumor therapyCD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasRecommendations for myeloid-derived suppressor cell nomenclature and characterization standardsThe IL-8/IL-8R Axis: A Double Agent in Tumor Immune ResistanceImmune Cells in Cancer Therapy and Drug DeliveryThe Role of Chemokines in Promoting Colorectal Cancer Invasion/MetastasisThe Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory DiseasesCancer-Associated Myeloid Regulatory CellsChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsParallel Aspects of the Microenvironment in Cancer and Autoimmune DiseaseNeutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor ProgressionTumor-Associated Macrophages and Neutrophils in Tumor MicroenvironmentInfluence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleMechanistic basis and clinical relevance of the role of transforming growth factor-β in cancerNeutrophils in Cancer: Two Sides of the Same CoinDistinct Functions of Neutrophil in Cancer and Its RegulationNeutrophil biology: an updateExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyHow Neutrophils Shape Adaptive Immune ResponsesEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityMyeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor MicroenvironmentGenetic instability in the tumor microenvironment: a new look at an old neighborMyeloid Cells as Targets for Therapy in Solid TumorsThe Role of Stroma in Tumor DevelopmentVaccines for pancreatic cancerThe gastrointestinal tumor microenvironmentIntertwined regulation of angiogenesis and immunity by myeloid cellsChemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic AgentsInflammation in arterial diseasesHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerImmune cell promotion of metastasisExtracellular matrix macromolecules: potential tools and targets in cancer gene therapyTransforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells
P2860
Q21245478-E90E6827-FF0B-4C44-8B12-755E7B870F95Q21296719-A688D20F-EF8E-47A9-9053-A3399591EF37Q24568136-213DD25E-03E5-48C9-B400-C433A35947EDQ24606406-D7B1CCCC-BFED-4562-BEB4-046644318D34Q26738293-BB271C5C-0FFA-4124-9080-6C91891D3F07Q26738682-4EAEE27F-D9ED-49A6-B0B1-3C12C321649EQ26740520-03FB6DDC-57D0-494B-B7EF-4EF8AE47B330Q26744395-95E215AD-E32B-4999-A926-2A59415F7A8BQ26746986-0490E5BD-2DAA-472F-BA9F-703F8C301823Q26747061-CDC2CB55-B4C6-4F02-B5EF-0856515B996DQ26748194-9FA58934-C189-42BD-BB3F-E422338018BCQ26749138-5C48CAE6-8DEB-4240-A123-EE222C54ABB7Q26750382-35095275-061F-4989-AA0B-674A9AB39106Q26753082-F6B7401D-659E-4A8F-ADAA-F1AB32F39E55Q26753174-FB3B3769-6CC7-4CCA-8DAA-12A845009C11Q26765238-64129A45-3047-47C7-B28C-8348FD4227CEQ26766429-FB172452-7503-4F1D-AB3B-FD1CC0BB8BACQ26767150-66F85AD5-BE67-4A03-8629-FC2F0E80381BQ26768652-F822A942-820F-4526-ADFE-B3A29D61E38DQ26769734-1E4E4657-629A-4E9B-9102-4EE7D7AE5A11Q26771386-CA80AC0F-0D43-4251-A41D-6E06499899BBQ26773072-3E9BF324-BD0F-44EB-BF0B-E268F019A112Q26773228-10508A55-C300-4F47-8280-AF69C0698CACQ26776297-5BC77379-EAAD-481C-86D1-3AC8329762CFQ26779184-6B0DC6F3-8B0C-4CD7-89ED-E46972F03DEFQ26781286-3FDA9FC2-2561-4E24-92D6-86A6C42CA8E6Q26796313-1DF2D7A0-324D-444B-9C76-2A0CC9E4B34EQ26799126-C02116B5-1FE7-4BB3-9D3C-60E52A0172FEQ26801374-CACA797E-F606-48DB-A7D2-7B39DC176685Q26801832-D6AC4E51-AB5C-49ED-B8ED-29DC9E14B979Q26801843-55FCC22E-4E33-4F05-8905-D3641886DF17Q26825850-0BCE1CB2-1EB8-4253-888E-E4AC990FEF6BQ26827391-AA8FD301-035E-4F78-9D9B-CE98F6B0F8D4Q26830418-453CDA14-3558-4994-B6D4-D1156A0D0288Q26830743-4DE4E59A-1729-45C7-B7FC-FC03380AF1A2Q26853576-8060BCF6-119E-4B98-B29B-096503D5EEEAQ26863418-E69D5217-5A8C-4B78-8BFE-340E42613411Q26991724-89FF4BC5-38F0-48CE-B19D-CC8A8FAEB476Q26996081-CB6AC9F8-D011-48AF-958F-954BF23DD1DCQ26996742-BD48036D-4AB5-4DD9-AE28-67329AA1BD59
P2860
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@ast
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@en
type
label
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@ast
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@en
prefLabel
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@ast
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@en
P2093
P2860
P3181
P1433
P1476
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
@en
P2093
Albelda SM
Fridlender ZG
Worthen GS
P2860
P304
P3181
P356
10.1016/J.CCR.2009.06.017
P407
P577
2009-09-08T00:00:00Z